OCT Evaluation of Neovascular AMD in Clinical Trials:
A Reading Center Perspective
This presentation will give the audience an overview of the role a reading center plays in the use of Optical Coherence Tomography (OCT) in major studies for patients with neovascular Age-related Macular Degeneration (nAMD). We will review the capabilities of the reading center and summarize how these studies are approached.
3 key questions that will be answered:
- What benefits does a reading center offer Sponsors pursuing nAMD studies with OCT endpoints?
- What are the common inclusion/exclusion eligibility criteria for OCT in nAMD studies?
- Which OCT endpoints are often used for nAMD studies?
Dr. Wilker is the current medical director of ophthalmology at MERIT. He is board-certified in ophthalmology and is a retinal specialist with over 15 years of clinical experience. At MERIT, he spearheads the development of evaluation procedures for ophthalmic imaging grading. Dr. Wilker’s roles include analyzing and reading images and/or data for ophthalmic clinical trials, performing reading quality control tasks, developing analysis and reading procedures for ophthalmic clinical trials, and providing training for readers. Dr. Wilker currently practices in Cleveland, OH.
Amanda WeberPARTNERSHIPS MANAGER AT MERIT
Amanda spearheads Business Development at MERIT and has over 15 years of experience in all aspects of consultative selling, from existing account management, lead generation to needs analysis, and client service. She is responsible for initial outreach communication while helping to identify new business relationship opportunities across MERIT’s therapeutic areas of expertise. Amanda researches, analyzes, and communicates the technological, demographic, financial, regulatory, and competitive factors that affect the business development strategies of MERIT.